Form 13-F position report

REDHILL BIOPHARMA LTD

Reported by MORGAN STANLEY

RDHL CUSIP 757468202 Manager CIK 0000895421

Reported 516 shares, down 60 (10.4%) from the prior quarter.

Reported value -67.5%; share count -10.4% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q1 2024
Shares 516 Quarter-end amount reported
Reported value $274 Fair value at quarter end
Consecutive quarters held 41 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 92000
2022-03-31 99000
2022-06-30 124000
2022-09-30 194000
2022-12-31 62477
2023-03-31 0
2023-03-31 1742
2023-06-30 721
2023-09-30 205
2023-12-31 842
2024-03-31 274
2024-06-30 134
2024-09-30 0
2024-09-30 1573
2024-12-31 13742
2025-03-31 34
2025-06-30 3496
2025-09-30 2
2025-12-31 0
2026-09-30 147

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for REDHILL BIOPHARMA LTD held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 306 +306 (0.0%) < 0.01% $147 2026-11-13
Q4 2025 Reduced 0 -1 (-100.0%) 0 $0 2026-02-13
Q3 2025 Reduced 1 -1,801 (-99.9%) < 0.01% $2 2025-11-14
Q2 2025 Added 1,802 +1,789 (13761.5%) < 0.01% $3,496 2025-08-15
Q1 2025 Reduced 13 -2,200 (-99.4%) < 0.01% $34 2025-05-15
Q4 2024 Added 2,213 +2,033 (1129.4%) < 0.01% $13,742 2025-02-14
Q3 2024 New 180 +180 (0.0%) < 0.01% $1,573 2024-11-14
Q3 2024 Reduced 0 -360 (-100.0%) 0 $0 2024-11-14
Q2 2024 Reduced 360 -156 (-30.2%) < 0.01% $134 2024-08-14
Q1 2024 Reduced 516 -60 (-10.4%) < 0.01% $274 2024-05-15
Q4 2023 Added 576 +175 (43.6%) < 0.01% $842 2024-02-13
Q3 2023 Reduced 401 -200 (-33.3%) < 0.01% $205 2023-11-15
Q2 2023 Added 601 +175 (41.1%) < 0.01% $721 2023-08-14
Q1 2023 New 426 +426 (0.0%) < 0.01% $1,742 2023-05-15
Q1 2023 Reduced 0 -445,309 (-100.0%) 0 $0 2023-05-15
Q4 2022 Added 445,309 +60,054 (15.6%) < 0.01% $62,477 2023-02-14
Q3 2022 Added 385,255 +242,697 (170.2%) < 0.01% $194,000 2022-11-14
Q2 2022 Added 142,558 +103,442 (264.4%) < 0.01% $124,000 2022-08-15
Q1 2022 Added 39,116 +3,596 (10.1%) < 0.01% $99,000 2022-05-13
Q4 2021 Added 35,520 +1,479 (4.3%) < 0.01% $92,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

23 managers reported REDHILL BIOPHARMA LTD for Q1 2024.

Managers reporting REDHILL BIOPHARMA LTD in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SABBY MANAGEMENT LLC New 2,319,238 +2,319,238 0.71% $1,228,964 3 qtrs
GAGNON SECURITIES LLC Added 118,360 +28,771 0.01% $62,719 3 qtrs
Federation des caisses Desjardins du Quebec Added 78,357 +10,155 < 0.01% $41,529 5 qtrs
UBS Group AG Added 50,592 +50,488 < 0.01% $26,814 5 qtrs
RHUMBLINE ADVISERS Reduced 30,187 -4,660 < 0.01% $15,876 4 qtrs
Virtu Financial LLC New 21,175 +21,175 < 0.01% $11,000 4 qtrs
MGO ONE SEVEN LLC Unchanged 15,750 0 < 0.01% $8,346 4 qtrs
TWO SIGMA SECURITIES LLC New 11,550 +11,550 < 0.01% $6,120 4 qtrs
GROUP ONE TRADING L P Unchanged 615 0 < 0.01% $323 5 qtrs
MORGAN STANLEY This report Reduced 516 -60 < 0.01% $274 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 15, 2024
Filing type
13F-HR
Position type
SPON ADS NEW

Voting authority reported

Sole
275
Shared
0
None
241

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.